# Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma

> **NCT01542918** · PHASE1 · COMPLETED · sponsor: **James Rubenstein** · enrollment: 14 (actual)

## Conditions studied

- Recurrent/Refractory CNS
- Intraocular Lymphoma

## Interventions

- **DRUG:** Lenalidomide
- **DRUG:** Rituximab

## Key facts

- **NCT ID:** NCT01542918
- **Lead sponsor:** James Rubenstein
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-12-17
- **Primary completion:** 2016-04-07
- **Final completion:** 2016-08-30
- **Target enrollment:** 14 (ACTUAL)
- **Last updated:** 2020-08-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01542918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01542918, "Lenalidomide Plus Rituximab for Recurrent/Refractory CNS and Intraocular Lymphoma". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT01542918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*